Alpelisib/Fulvestrant Combination Wins Philippine Approval for PIK3CA-Mutated, HR+/HER2– Metastatic Breast Cancer - OncLive
7/18/2022 12:00:00 AM2 years 9 months ago
by Chris Ryan
by Chris Ryan
The Philippine FDA has granted approval to alpelisib in combination with fulvestrant for the treatment of patients with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.
The Philippine FDA has granted approval to alpelisib (Vijoice) in combination with fulvestrant (Faslodex) for the treatment of patients with PIK3CA-mutated, hormone receptor (HR)positive, HER2-negati… [+4609 chars]
full article...